TargetMol

Baricitinib

Product Code:
 
TAR-T2485
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2485-2mg2mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2485-5mg5mg£117.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2485-1mL1 mL * 10 mM (in DMSO)£123.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2485-10mg10mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2485-25mg25mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2485-50mg50mg£166.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2485-100mg100mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.
CAS:
1187594-09-7
Formula:
C16H17N7O2S
Molecular Weight:
371.42
Pathway:
Stem Cells; Tyrosine Kinase/Adaptors; JAK/STAT signaling; Chromatin/Epigenetic; Angiogenesis; Cell Cycle/Checkpoint
Purity:
0.9979
SMILES:
CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1[nH]cnc2nccc12
Target:
Tyrosine Kinases; JAK; Chk

References

1. Fridman JS, et al. J Immunol, 2010, 184(9), 5298-5307. 2. Kontzias A, et al. Curr Opin Pharmacol, 2012, 12(4), 464-470. 3. Norman P, et al. Expert Opin Ther Pat, 2012, 22(10), 1233-1249. 4. Norman P, et al. Expert Opin Ther Pat, 2012, 22(9), 1105-1109. 5. Kvacskay P, Yao N, Schnotz J H, et al. Increase of aerobic glycolysis mediated by activated T helper cells drives synovial fibroblasts towards an inflammatory phenotype: new targets for therapy?[J]. Arthritis Research & Therapy. 2021, 23(1): 1-15.